SlideShare una empresa de Scribd logo
1 de 30
Descargar para leer sin conexión
Influenza: Facts and
prevention
By
Dr. Moustapha A. Ramadan
Objectives of the session
 Epidemiology of influenza
 Difference between influenza and
common cold
 Virulence of influenza
 Prevention of influenza
Influenza Virus Strains
 Type A- moderate to severe illness
- all age groups
- humans and other animals
 Type B- milder disease
- primarily affects children
- humans only
 Type C- rarely reported in humans
- no epidemics
Influenza Epidemiology
 Reservoir Human, animals (type
A only)
 Transmission Contact (Direct-indirect-
droplet)
Airborne
 Temporal pattern Peak December – March
in temperate climate
May occur earlier or later
 Incubation period 1-3 days
 Communicability 1 day before to 5 days
after onset (adults)
Influenza Virus
A/Fujian/411/2002 (H3N2)
Neuraminidase
Hemagglutinin
Type of nuclear
material
Virus
type
Geographic
origin
Strain
number
Year of
isolation
Virus
subtype
Species Infected by Influenza A,
HA and NA Subtypes
H15,16
H14
H13
H12
H11
H10
H3
H2
H1
H9
H8
H7
H6
H5
H4
N9
N8
N7
N6
N5
N3
N4
N2
N1
Influenza Antigenic Changes
 Antigenic Shift
◦ major change, new subtype
◦ caused by exchange of gene segments
◦ may result in pandemic
 Example of antigenic shift
◦ H2N2 virus circulated in 1957-1967
◦ H3N2 virus appeared in 1968 and completely
replaced H2N2 virus
Influenza Antigenic Changes
 Antigenic Drift
◦ minor change, same subtype
◦ caused by point mutations in gene
◦ may result in epidemic
 Example of antigenic drift
◦ in 2002-2003, A/Panama/2007/99 (H3N2)
virus was dominant
◦ A/Fujian/411/2002 (H3N2) appeared in late
2003 and caused widespread illness in 2003-
2004
Influenza Type A Antigenic Shifts
Year
1889
1918
1957
1968
1977
Subtype
H3N2
H1N1
H2N2
H3N2
H1N1
Severity of
Pandemic
Moderate
Severe
Severe
Moderate
Mild
Influenza facts and prevention
Influenza facts and prevention
What are the symptoms of
influenza in humans?
The symptoms of different forms of influenza in people
tend to be similar and include
*Fever > 37.8°C
*Sore throat
*Cough
*Runny nose
*Chills
*Headache and body aches
*Fatigue
Some people have reported nausea, vomiting and
diarrhea.
 How is swine flu different from avian (bird)
flu?
Avian flu so far has had difficulty infecting humans unless
they are exposed intensely to birds, because the virus
has not mutated in a way that makes it transmissible by
humans to other humans. Swine virus has origins
genetically from both pigs and birds, and the big
difference from the avian flu is that the swine virus can
be transmitted readily from human to human.
 Is this just another scare that will go
away like bird flu?
Bird flu is a theoretical threat and will need a
mutation to be able to be transmitted among
humans to become a serious threat.
There is logical concern that swine flu might
re-emerge next flu season.
 Can influenza kill me?
Morbidity tends to be high and mortality low (1–
4%).
3-5 millions are affected yearly, 250 000-500 000
deaths yearly
We do not know all the factors geographically
and demographically that may contribute to the
mildness or severity of this flu.
What is the morbidity and mortality?
Avian flu H5 N1
Worldwide Total 505 Death 300 (59.4%)
Egypt Total 112 Death 36 ( 32.14%)
Swine flu H1 N1
Worldwide Total 8753967 Death 14346 (0. 16%)
Egypt Total 12230 Death 195 (1. 59%)
 What are the preventive methods for me
and contacts?
Proper hand hygiene
Coughing etiquette
Avoid overcrowded places
Avoid bad ventilated places
If you are ill, stay home.
Immunization
Surveillance by health authorities of the extent
and progress of the outbreak and reporting of
findings to the community is important.
Influenza facts and prevention
What are the types of influenza vaccine
available?
 There are two forms for influenza vaccine
Inactivated Form and Live attenuated Form.
 During any outbreak the influenza vaccine is
made using the same process and facilities that
are used to make the currently licensed seasonal
influenza vaccines.
 During outbreak people willing to have the
vaccine should have both
 The vaccine is usually available at fall.
Who will be covered by the vaccine ?
 WHO currently estimates worldwide production capacity
for pandemic vaccines at approximately 3 billion doses
per year
 These supplies will still be inadequate to cover a world
population of 6.8 billion people in which virtually
everyone is susceptible to infection
 Vaccine supplies in low and middle income countries will
largely depend on donations from manufacturers and
other countries
Who is recommended to receive the
vaccine?
 Infants younger than 6 months of age ;
 Persons aged 65 years or older
 Pregnant women
 Persons of any age with certain chronic medical or
immunosuppressive conditions and ,
 Persons younger than 19 years of age who are
receiving long-term aspirin therapy .
 Healthcare personnel and emergency medical
services personnel.
What are the side effects of vaccine?
 In almost all vaccine recipients, symptoms are mild, self-
limited and last 1-2 days.
 Side effects are expected to be similar to those observed
with seasonal influenza vaccines :
 Local reaction at the injection site ( soreness, swelling,
redness)
 Systemic reaction (fever, headache, muscle or joint
aches)
 What medications are available for
influenza infections treatment/
chemoprophylaxis in humans?
There are four different antiviral drugs that are licensed
for use in the US for the treatment of influenza:
Amantadine, Rimantadine, Oseltamivir and
Zanamivir.
To whom chemoprophylaxis is
recommended?
 Persons who are at higher risk for complications of
influenza and are at close contact of a person with
confirmed, probable, or suspected influenza during
person’s infectious period.
 Health care personnel, public health workers, or first
responders who have had a recognized, unprotected
close contact exposure to a person with confirmed,
probable, or suspected influenza during person’s
infectious period.
When chemoprophylaxis is not
considered?
 Antiviral agents should not be used for post exposure
chemoprophylaxis in healthy children or adults based on
potential exposures in the community, school, camp or
other settings .
 Chemoprophylaxis generally is not recommended if
more than 48 hours have elapsed since the last contact
with an infectious person .
 Chemoprophylaxis is not indicated when contact
occurred before or after, but not during, the period of
communicability.
What are the treatment
recommendations?
Early empiric treatment with antiviral drugs should be
considered for persons with suspected or confirmed
influenza who are at higher risk for complications
including:
 Children younger than 2 years old ;
 Persons aged 65 years or older
 Pregnant women
 Persons of any age with certain chronic medical or
immunosuppressive conditions and ,
 Persons younger than 19 years of age who are receiving long-
term aspirin therapy .
Treatment with antiviral drugs is recommended for all
persons with suspected or confirmed influenza
requiring hospitalization.
What are the treatment
recommendations?
 Treatment, when indicated, should be initiated as early
as possible (i.e., within 48 hours of illness onset) is more
likely to be benefit .
 Treatment should not wait for laboratory confirmation of
influenza because laboratory testing can delay treatment
and because a negative rapid test for influenza does not
rule out influenza .
What is the antiviral dosage?
 Oseltamivir
Treatment: 75-mg capsule twice per day for 5 days
Chemoprophylaxis: 75-mg capsule once per day for 10
days
 Zanamivir
Treatment :10 mg (two 5-mg inhalations) twice daily for 5
days
Chemoprophylaxis :10 mg (two 5-mg inhalations) once
daily for 10 days
What are the antiviral agents side
effects?
 Oseltamivir
Nausea, vomiting( less severe if taken with food)
Transient neuropsychiatric event ) self injury, delirium) have
been reported in adults living in Japan
 Zanamivir
Diarrhea, nausea, sinusitis, bronchitis, cough, headache,
dizziness
Each of these symptoms was reported by less than 5%
Is not recommended for patients with underlying airway disease
 References:
World Health Organization (WHO)
Centre for disease control (CDC)
Control of communicable diseases manual
Infection control today

Más contenido relacionado

La actualidad más candente (20)

Influenza Virus
Influenza VirusInfluenza Virus
Influenza Virus
 
swine Flu Influenza Pptx
swine Flu Influenza Pptxswine Flu Influenza Pptx
swine Flu Influenza Pptx
 
Emerging and re emerging diseases
Emerging and re emerging diseasesEmerging and re emerging diseases
Emerging and re emerging diseases
 
Dengue virus
Dengue virus  Dengue virus
Dengue virus
 
Swine flu ppt
Swine flu pptSwine flu ppt
Swine flu ppt
 
Nipah virus ppt
Nipah virus pptNipah virus ppt
Nipah virus ppt
 
9 emerging and reemerging diseases
9 emerging and reemerging diseases9 emerging and reemerging diseases
9 emerging and reemerging diseases
 
Seasonal Influenza
Seasonal InfluenzaSeasonal Influenza
Seasonal Influenza
 
Japanese encephalitis epidemiology
Japanese encephalitis epidemiologyJapanese encephalitis epidemiology
Japanese encephalitis epidemiology
 
Influenza
InfluenzaInfluenza
Influenza
 
Smallpox disease
Smallpox diseaseSmallpox disease
Smallpox disease
 
Emerging & re emerging infections
Emerging & re emerging infectionsEmerging & re emerging infections
Emerging & re emerging infections
 
Influenza virus-Flu
Influenza virus-FluInfluenza virus-Flu
Influenza virus-Flu
 
Influenza
InfluenzaInfluenza
Influenza
 
SMALL POX A DEAD DISEASE
SMALL POX A DEAD DISEASE SMALL POX A DEAD DISEASE
SMALL POX A DEAD DISEASE
 
Measles - Epidemiology and Control
Measles - Epidemiology and ControlMeasles - Epidemiology and Control
Measles - Epidemiology and Control
 
AIDS
AIDSAIDS
AIDS
 
Smallpox
Smallpox Smallpox
Smallpox
 
swine flu
swine fluswine flu
swine flu
 
Influenza
InfluenzaInfluenza
Influenza
 

Destacado

Drug interactions in pharmacy related practice j. bolt
Drug interactions in pharmacy related practice j. boltDrug interactions in pharmacy related practice j. bolt
Drug interactions in pharmacy related practice j. boltPASaskatchewan
 
Acute bronchitis in children
Acute bronchitis in childrenAcute bronchitis in children
Acute bronchitis in childrenFabio Grubba
 
McKesson Case Study: Pharmacy Systems & Automation
McKesson Case Study: Pharmacy Systems & AutomationMcKesson Case Study: Pharmacy Systems & Automation
McKesson Case Study: Pharmacy Systems & AutomationForgeRock
 
Case Study - Pediatric - Pancreatitis - Septic Shock
Case Study - Pediatric - Pancreatitis - Septic ShockCase Study - Pediatric - Pancreatitis - Septic Shock
Case Study - Pediatric - Pancreatitis - Septic ShockUscom - Case Studies
 
Antibiotic resistance in bacteria 1
Antibiotic resistance in bacteria 1Antibiotic resistance in bacteria 1
Antibiotic resistance in bacteria 1anusil
 
Case prsentation from Port fouad hospital, Port said
Case prsentation from Port fouad hospital, Port saidCase prsentation from Port fouad hospital, Port said
Case prsentation from Port fouad hospital, Port saidmohamed osama hussein
 
Vaccines: Linking Awareness, Access, and Action
Vaccines: Linking Awareness, Access, and ActionVaccines: Linking Awareness, Access, and Action
Vaccines: Linking Awareness, Access, and ActionRx EDGE
 
Telehealth & Pediatric Obesity
Telehealth & Pediatric ObesityTelehealth & Pediatric Obesity
Telehealth & Pediatric ObesityNajib Momin
 
Pediatric Case Study
Pediatric Case Study Pediatric Case Study
Pediatric Case Study abortnick
 
Acute anaphylaxis and anaphylactic reactions
Acute anaphylaxis and anaphylactic reactionsAcute anaphylaxis and anaphylactic reactions
Acute anaphylaxis and anaphylactic reactionsdani raad
 
Case Study - Pediatric - Septic Shock
Case Study - Pediatric - Septic ShockCase Study - Pediatric - Septic Shock
Case Study - Pediatric - Septic ShockUscom - Case Studies
 
Case Study - Pediatric - Meningococcemia - Septic Shock
Case Study - Pediatric - Meningococcemia - Septic ShockCase Study - Pediatric - Meningococcemia - Septic Shock
Case Study - Pediatric - Meningococcemia - Septic ShockUscom - Case Studies
 
Incompatibilities of drug admixtures
Incompatibilities of drug admixtures Incompatibilities of drug admixtures
Incompatibilities of drug admixtures Ali Al Samawy
 
Kim, stacy cnmc case study presentation
Kim, stacy   cnmc case study presentationKim, stacy   cnmc case study presentation
Kim, stacy cnmc case study presentationdkim930
 
PEDIATRIC DEPARTMENT
PEDIATRIC DEPARTMENTPEDIATRIC DEPARTMENT
PEDIATRIC DEPARTMENTDipali Liman
 

Destacado (20)

Drug interactions in pharmacy related practice j. bolt
Drug interactions in pharmacy related practice j. boltDrug interactions in pharmacy related practice j. bolt
Drug interactions in pharmacy related practice j. bolt
 
Acute bronchitis in children
Acute bronchitis in childrenAcute bronchitis in children
Acute bronchitis in children
 
McKesson Case Study: Pharmacy Systems & Automation
McKesson Case Study: Pharmacy Systems & AutomationMcKesson Case Study: Pharmacy Systems & Automation
McKesson Case Study: Pharmacy Systems & Automation
 
Case Study - Pediatric - Pancreatitis - Septic Shock
Case Study - Pediatric - Pancreatitis - Septic ShockCase Study - Pediatric - Pancreatitis - Septic Shock
Case Study - Pediatric - Pancreatitis - Septic Shock
 
Antibiotic resistance in bacteria 1
Antibiotic resistance in bacteria 1Antibiotic resistance in bacteria 1
Antibiotic resistance in bacteria 1
 
Hypersensitivity
HypersensitivityHypersensitivity
Hypersensitivity
 
Case prsentation from Port fouad hospital, Port said
Case prsentation from Port fouad hospital, Port saidCase prsentation from Port fouad hospital, Port said
Case prsentation from Port fouad hospital, Port said
 
antibiotic-sensitivity testing
antibiotic-sensitivity testingantibiotic-sensitivity testing
antibiotic-sensitivity testing
 
Shock
ShockShock
Shock
 
Vaccines: Linking Awareness, Access, and Action
Vaccines: Linking Awareness, Access, and ActionVaccines: Linking Awareness, Access, and Action
Vaccines: Linking Awareness, Access, and Action
 
Telehealth & Pediatric Obesity
Telehealth & Pediatric ObesityTelehealth & Pediatric Obesity
Telehealth & Pediatric Obesity
 
Pediatric Case Study
Pediatric Case Study Pediatric Case Study
Pediatric Case Study
 
Septic shock
Septic shockSeptic shock
Septic shock
 
Acute anaphylaxis and anaphylactic reactions
Acute anaphylaxis and anaphylactic reactionsAcute anaphylaxis and anaphylactic reactions
Acute anaphylaxis and anaphylactic reactions
 
Case Study - Pediatric - Septic Shock
Case Study - Pediatric - Septic ShockCase Study - Pediatric - Septic Shock
Case Study - Pediatric - Septic Shock
 
SHOCK
SHOCKSHOCK
SHOCK
 
Case Study - Pediatric - Meningococcemia - Septic Shock
Case Study - Pediatric - Meningococcemia - Septic ShockCase Study - Pediatric - Meningococcemia - Septic Shock
Case Study - Pediatric - Meningococcemia - Septic Shock
 
Incompatibilities of drug admixtures
Incompatibilities of drug admixtures Incompatibilities of drug admixtures
Incompatibilities of drug admixtures
 
Kim, stacy cnmc case study presentation
Kim, stacy   cnmc case study presentationKim, stacy   cnmc case study presentation
Kim, stacy cnmc case study presentation
 
PEDIATRIC DEPARTMENT
PEDIATRIC DEPARTMENTPEDIATRIC DEPARTMENT
PEDIATRIC DEPARTMENT
 

Similar a Influenza facts and prevention

Influenz1.docx
Influenz1.docxInfluenz1.docx
Influenz1.docxKoh Fenqi
 
Swine Flu
Swine FluSwine Flu
Swine Fluohogi
 
Vaccine4 influenza
Vaccine4 influenzaVaccine4 influenza
Vaccine4 influenzaJasmine John
 
Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment   Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment Ashraf ElAdawy
 
Pandemic H1 N1 Influenza
Pandemic H1 N1 InfluenzaPandemic H1 N1 Influenza
Pandemic H1 N1 Influenzahappyneige
 
2009 Sept 1 Nwrc H1 N1
2009 Sept 1 Nwrc H1 N12009 Sept 1 Nwrc H1 N1
2009 Sept 1 Nwrc H1 N1egermann
 
Adult Vaccine 2013 final
 Adult Vaccine 2013 final Adult Vaccine 2013 final
Adult Vaccine 2013 finalahmed saad
 
Influenza Essay Example
Influenza Essay ExampleInfluenza Essay Example
Influenza Essay ExampleJill Baldwin
 
EPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptx
EPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptxEPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptx
EPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptxYogeswaranElangovan2
 
Swineflu dr rs matoria
Swineflu dr rs matoriaSwineflu dr rs matoria
Swineflu dr rs matoriaRam Matoria
 
Swine flu- Pandemic Influenza A (H1N1)
Swine flu- Pandemic Influenza A (H1N1)Swine flu- Pandemic Influenza A (H1N1)
Swine flu- Pandemic Influenza A (H1N1)Sumi Singh
 
Travel related infectious disease 2.pptx
Travel related infectious disease 2.pptxTravel related infectious disease 2.pptx
Travel related infectious disease 2.pptxGovindRankawat1
 
Introspecting into Swine flu: Current updates
Introspecting into Swine flu: Current updatesIntrospecting into Swine flu: Current updates
Introspecting into Swine flu: Current updatesArnab Nandy
 

Similar a Influenza facts and prevention (20)

Influenz1.docx
Influenz1.docxInfluenz1.docx
Influenz1.docx
 
Swine Flu
Swine FluSwine Flu
Swine Flu
 
Vaccine4 influenza
Vaccine4 influenzaVaccine4 influenza
Vaccine4 influenza
 
Influenza8p
Influenza8pInfluenza8p
Influenza8p
 
Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment   Influenza in Children Recommendations for Prevention &Treatment
Influenza in Children Recommendations for Prevention &Treatment
 
Influenza
InfluenzaInfluenza
Influenza
 
Pandemic H1 N1 Influenza
Pandemic H1 N1 InfluenzaPandemic H1 N1 Influenza
Pandemic H1 N1 Influenza
 
2009 Sept 1 Nwrc H1 N1
2009 Sept 1 Nwrc H1 N12009 Sept 1 Nwrc H1 N1
2009 Sept 1 Nwrc H1 N1
 
Adult Vaccine 2013 final
 Adult Vaccine 2013 final Adult Vaccine 2013 final
Adult Vaccine 2013 final
 
Influenza Essay Example
Influenza Essay ExampleInfluenza Essay Example
Influenza Essay Example
 
influenza.pptx
influenza.pptxinfluenza.pptx
influenza.pptx
 
EPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptx
EPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptxEPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptx
EPIDEMIOLOGY OF YELLOW FEVER AND ITS PREVENTION AND.pptx
 
Influenza
InfluenzaInfluenza
Influenza
 
Swineflu dr rs matoria
Swineflu dr rs matoriaSwineflu dr rs matoria
Swineflu dr rs matoria
 
H1 N1
H1 N1H1 N1
H1 N1
 
Swine flu- Pandemic Influenza A (H1N1)
Swine flu- Pandemic Influenza A (H1N1)Swine flu- Pandemic Influenza A (H1N1)
Swine flu- Pandemic Influenza A (H1N1)
 
Swine Flu Update Dec'09
Swine Flu Update Dec'09Swine Flu Update Dec'09
Swine Flu Update Dec'09
 
Travel related infectious disease 2.pptx
Travel related infectious disease 2.pptxTravel related infectious disease 2.pptx
Travel related infectious disease 2.pptx
 
Influenza
InfluenzaInfluenza
Influenza
 
Introspecting into Swine flu: Current updates
Introspecting into Swine flu: Current updatesIntrospecting into Swine flu: Current updates
Introspecting into Swine flu: Current updates
 

Más de Moustapha Ramadan

Role of infection control during emergency crisis
Role of infection control during emergency crisisRole of infection control during emergency crisis
Role of infection control during emergency crisisMoustapha Ramadan
 
Influenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilitiesInfluenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilitiesMoustapha Ramadan
 
Prevention of blood stream infection
Prevention of blood stream infectionPrevention of blood stream infection
Prevention of blood stream infectionMoustapha Ramadan
 
New technologies in environmental cleaning
New technologies in environmental cleaningNew technologies in environmental cleaning
New technologies in environmental cleaningMoustapha Ramadan
 
Infection control precautions in cholera outbreak
Infection control precautions in cholera outbreakInfection control precautions in cholera outbreak
Infection control precautions in cholera outbreakMoustapha Ramadan
 
Prevention of mycobateria tuberculosis in healthcare settings
Prevention of mycobateria tuberculosis in healthcare settingsPrevention of mycobateria tuberculosis in healthcare settings
Prevention of mycobateria tuberculosis in healthcare settingsMoustapha Ramadan
 
Prevention strategy for mdro in hospital
Prevention strategy for mdro in hospitalPrevention strategy for mdro in hospital
Prevention strategy for mdro in hospitalMoustapha Ramadan
 
Infection prevention in healthcare construction and renovation
Infection prevention in healthcare construction and renovationInfection prevention in healthcare construction and renovation
Infection prevention in healthcare construction and renovationMoustapha Ramadan
 
Management of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuriesManagement of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuriesMoustapha Ramadan
 
Infection Control and Antibiotic resistance
Infection Control and Antibiotic resistanceInfection Control and Antibiotic resistance
Infection Control and Antibiotic resistanceMoustapha Ramadan
 
Infection control in operation room
Infection control in operation roomInfection control in operation room
Infection control in operation roomMoustapha Ramadan
 
Investigation of epidemic presentation
Investigation of epidemic presentationInvestigation of epidemic presentation
Investigation of epidemic presentationMoustapha Ramadan
 
Human papilloma virus vaccine - Egypt
Human papilloma virus vaccine - EgyptHuman papilloma virus vaccine - Egypt
Human papilloma virus vaccine - EgyptMoustapha Ramadan
 

Más de Moustapha Ramadan (14)

Role of infection control during emergency crisis
Role of infection control during emergency crisisRole of infection control during emergency crisis
Role of infection control during emergency crisis
 
Influenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilitiesInfluenza a emergency prepardness for healthcare facilities
Influenza a emergency prepardness for healthcare facilities
 
Prevention of blood stream infection
Prevention of blood stream infectionPrevention of blood stream infection
Prevention of blood stream infection
 
New technologies in environmental cleaning
New technologies in environmental cleaningNew technologies in environmental cleaning
New technologies in environmental cleaning
 
Injection safety
Injection safetyInjection safety
Injection safety
 
Infection control precautions in cholera outbreak
Infection control precautions in cholera outbreakInfection control precautions in cholera outbreak
Infection control precautions in cholera outbreak
 
Prevention of mycobateria tuberculosis in healthcare settings
Prevention of mycobateria tuberculosis in healthcare settingsPrevention of mycobateria tuberculosis in healthcare settings
Prevention of mycobateria tuberculosis in healthcare settings
 
Prevention strategy for mdro in hospital
Prevention strategy for mdro in hospitalPrevention strategy for mdro in hospital
Prevention strategy for mdro in hospital
 
Infection prevention in healthcare construction and renovation
Infection prevention in healthcare construction and renovationInfection prevention in healthcare construction and renovation
Infection prevention in healthcare construction and renovation
 
Management of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuriesManagement of blood exposure and needle stick injuries
Management of blood exposure and needle stick injuries
 
Infection Control and Antibiotic resistance
Infection Control and Antibiotic resistanceInfection Control and Antibiotic resistance
Infection Control and Antibiotic resistance
 
Infection control in operation room
Infection control in operation roomInfection control in operation room
Infection control in operation room
 
Investigation of epidemic presentation
Investigation of epidemic presentationInvestigation of epidemic presentation
Investigation of epidemic presentation
 
Human papilloma virus vaccine - Egypt
Human papilloma virus vaccine - EgyptHuman papilloma virus vaccine - Egypt
Human papilloma virus vaccine - Egypt
 

Último

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfMedicoseAcademics
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)Mohamed Rizk Khodair
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 

Último (20)

"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Pregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdfPregnacny, Parturition, and Lactation.pdf
Pregnacny, Parturition, and Lactation.pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)introduction to neurology (nervous system, areas, motor and sensory systems)
introduction to neurology (nervous system, areas, motor and sensory systems)
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 

Influenza facts and prevention

  • 2. Objectives of the session  Epidemiology of influenza  Difference between influenza and common cold  Virulence of influenza  Prevention of influenza
  • 3. Influenza Virus Strains  Type A- moderate to severe illness - all age groups - humans and other animals  Type B- milder disease - primarily affects children - humans only  Type C- rarely reported in humans - no epidemics
  • 4. Influenza Epidemiology  Reservoir Human, animals (type A only)  Transmission Contact (Direct-indirect- droplet) Airborne  Temporal pattern Peak December – March in temperate climate May occur earlier or later  Incubation period 1-3 days  Communicability 1 day before to 5 days after onset (adults)
  • 5. Influenza Virus A/Fujian/411/2002 (H3N2) Neuraminidase Hemagglutinin Type of nuclear material Virus type Geographic origin Strain number Year of isolation Virus subtype
  • 6. Species Infected by Influenza A, HA and NA Subtypes H15,16 H14 H13 H12 H11 H10 H3 H2 H1 H9 H8 H7 H6 H5 H4 N9 N8 N7 N6 N5 N3 N4 N2 N1
  • 7. Influenza Antigenic Changes  Antigenic Shift ◦ major change, new subtype ◦ caused by exchange of gene segments ◦ may result in pandemic  Example of antigenic shift ◦ H2N2 virus circulated in 1957-1967 ◦ H3N2 virus appeared in 1968 and completely replaced H2N2 virus
  • 8. Influenza Antigenic Changes  Antigenic Drift ◦ minor change, same subtype ◦ caused by point mutations in gene ◦ may result in epidemic  Example of antigenic drift ◦ in 2002-2003, A/Panama/2007/99 (H3N2) virus was dominant ◦ A/Fujian/411/2002 (H3N2) appeared in late 2003 and caused widespread illness in 2003- 2004
  • 9. Influenza Type A Antigenic Shifts Year 1889 1918 1957 1968 1977 Subtype H3N2 H1N1 H2N2 H3N2 H1N1 Severity of Pandemic Moderate Severe Severe Moderate Mild
  • 12. What are the symptoms of influenza in humans? The symptoms of different forms of influenza in people tend to be similar and include *Fever > 37.8°C *Sore throat *Cough *Runny nose *Chills *Headache and body aches *Fatigue Some people have reported nausea, vomiting and diarrhea.
  • 13.  How is swine flu different from avian (bird) flu? Avian flu so far has had difficulty infecting humans unless they are exposed intensely to birds, because the virus has not mutated in a way that makes it transmissible by humans to other humans. Swine virus has origins genetically from both pigs and birds, and the big difference from the avian flu is that the swine virus can be transmitted readily from human to human.
  • 14.  Is this just another scare that will go away like bird flu? Bird flu is a theoretical threat and will need a mutation to be able to be transmitted among humans to become a serious threat. There is logical concern that swine flu might re-emerge next flu season.
  • 15.  Can influenza kill me? Morbidity tends to be high and mortality low (1– 4%). 3-5 millions are affected yearly, 250 000-500 000 deaths yearly We do not know all the factors geographically and demographically that may contribute to the mildness or severity of this flu.
  • 16. What is the morbidity and mortality? Avian flu H5 N1 Worldwide Total 505 Death 300 (59.4%) Egypt Total 112 Death 36 ( 32.14%) Swine flu H1 N1 Worldwide Total 8753967 Death 14346 (0. 16%) Egypt Total 12230 Death 195 (1. 59%)
  • 17.  What are the preventive methods for me and contacts? Proper hand hygiene Coughing etiquette Avoid overcrowded places Avoid bad ventilated places If you are ill, stay home. Immunization Surveillance by health authorities of the extent and progress of the outbreak and reporting of findings to the community is important.
  • 19. What are the types of influenza vaccine available?  There are two forms for influenza vaccine Inactivated Form and Live attenuated Form.  During any outbreak the influenza vaccine is made using the same process and facilities that are used to make the currently licensed seasonal influenza vaccines.  During outbreak people willing to have the vaccine should have both  The vaccine is usually available at fall.
  • 20. Who will be covered by the vaccine ?  WHO currently estimates worldwide production capacity for pandemic vaccines at approximately 3 billion doses per year  These supplies will still be inadequate to cover a world population of 6.8 billion people in which virtually everyone is susceptible to infection  Vaccine supplies in low and middle income countries will largely depend on donations from manufacturers and other countries
  • 21. Who is recommended to receive the vaccine?  Infants younger than 6 months of age ;  Persons aged 65 years or older  Pregnant women  Persons of any age with certain chronic medical or immunosuppressive conditions and ,  Persons younger than 19 years of age who are receiving long-term aspirin therapy .  Healthcare personnel and emergency medical services personnel.
  • 22. What are the side effects of vaccine?  In almost all vaccine recipients, symptoms are mild, self- limited and last 1-2 days.  Side effects are expected to be similar to those observed with seasonal influenza vaccines :  Local reaction at the injection site ( soreness, swelling, redness)  Systemic reaction (fever, headache, muscle or joint aches)
  • 23.  What medications are available for influenza infections treatment/ chemoprophylaxis in humans? There are four different antiviral drugs that are licensed for use in the US for the treatment of influenza: Amantadine, Rimantadine, Oseltamivir and Zanamivir.
  • 24. To whom chemoprophylaxis is recommended?  Persons who are at higher risk for complications of influenza and are at close contact of a person with confirmed, probable, or suspected influenza during person’s infectious period.  Health care personnel, public health workers, or first responders who have had a recognized, unprotected close contact exposure to a person with confirmed, probable, or suspected influenza during person’s infectious period.
  • 25. When chemoprophylaxis is not considered?  Antiviral agents should not be used for post exposure chemoprophylaxis in healthy children or adults based on potential exposures in the community, school, camp or other settings .  Chemoprophylaxis generally is not recommended if more than 48 hours have elapsed since the last contact with an infectious person .  Chemoprophylaxis is not indicated when contact occurred before or after, but not during, the period of communicability.
  • 26. What are the treatment recommendations? Early empiric treatment with antiviral drugs should be considered for persons with suspected or confirmed influenza who are at higher risk for complications including:  Children younger than 2 years old ;  Persons aged 65 years or older  Pregnant women  Persons of any age with certain chronic medical or immunosuppressive conditions and ,  Persons younger than 19 years of age who are receiving long- term aspirin therapy . Treatment with antiviral drugs is recommended for all persons with suspected or confirmed influenza requiring hospitalization.
  • 27. What are the treatment recommendations?  Treatment, when indicated, should be initiated as early as possible (i.e., within 48 hours of illness onset) is more likely to be benefit .  Treatment should not wait for laboratory confirmation of influenza because laboratory testing can delay treatment and because a negative rapid test for influenza does not rule out influenza .
  • 28. What is the antiviral dosage?  Oseltamivir Treatment: 75-mg capsule twice per day for 5 days Chemoprophylaxis: 75-mg capsule once per day for 10 days  Zanamivir Treatment :10 mg (two 5-mg inhalations) twice daily for 5 days Chemoprophylaxis :10 mg (two 5-mg inhalations) once daily for 10 days
  • 29. What are the antiviral agents side effects?  Oseltamivir Nausea, vomiting( less severe if taken with food) Transient neuropsychiatric event ) self injury, delirium) have been reported in adults living in Japan  Zanamivir Diarrhea, nausea, sinusitis, bronchitis, cough, headache, dizziness Each of these symptoms was reported by less than 5% Is not recommended for patients with underlying airway disease
  • 30.  References: World Health Organization (WHO) Centre for disease control (CDC) Control of communicable diseases manual Infection control today